The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 ...

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the ...

Also, resistant cells can harbor activating mutations in PI3K or Akt ... ADCC, antibody-dependent cellular cytotoxicity; Akt, protein kinase B; c-Cbl, Casitas B-lineage lymphoma; CDK2, ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Subclones of these cells may acquire independent genetic changes to produce non-Hodgkin lymphomas and Hodgkin lymphoma. Another speculation is that the multiclonal lymphocytes may proliferate in a ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price ...

This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...